What one share of Acumen Pharmaceuticals holds
We are a clinical-stage biopharmaceutical company developing a novel disease-modifying approach targeting what we believe to be a key underlying cause of Alzheimer’s disease, or AD. Alzheimer’s disease is a progressive neurodegenerative disease of the brain that leads to loss of memory and cognitive functions and ultimately results in death.
Acumen Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.64 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.43 |
| Cash and investments | $1.52 |
| Debt | $0.44 |
| Book value | $0.79 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$17.48 | — | — | — | −$44.36 |
| 2021 | — | −$5.02 | $0.00 | −$0.90 | — | — |
| 2022 | — | −$1.06 | $0.00 | −$0.87 | — | $4.60 |
| 2023 | — | −$1.08 | $0.00 | −$0.89 | — | $4.61 |
| 2024 | — | −$1.71 | $0.00 | −$1.44 | — | $3.03 |
| 2025 | — | −$2.00 | $0.00 | −$1.91 | — | $1.16 |
Common questions about Acumen Pharmaceuticals
How much does one share of Acumen Pharmaceuticals earn?
Over the last 12 months, Acumen Pharmaceuticals lost $1.64 for each share.
Does Acumen Pharmaceuticals pay a dividend?
Acumen Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Acumen Pharmaceuticals’s book value per share?
Acumen Pharmaceuticals’s book value is $0.79 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Acumen Pharmaceuticals have?
Each share of Acumen Pharmaceuticals has $1.52 of cash and investments and $0.44 of debt, as of June 30, 2026.
What is Acumen Pharmaceuticals’s free cash flow per share?
−$1.43 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Acumen Pharmaceuticals bought back shares?
Acumen Pharmaceuticals’s share count rose about 14350% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.